OncoMatch/Clinical Trials/NCT07872553
A Study of Treatment Delivery Preference In People With Kidney Cancer
Official title: Subcutaneous Versus Intravenous Immune Checkpoint Inhibitors, Treatment Burden, and Care Delivery for Patients With Renal Cell Carcinoma
Is NCT07872553 recruiting? Yes, currently enrolling (Oct 2026). This Phase 4 trial studies multiple treatments including Nivolumab Injectable Product and Nivolumab for renal cell carcinoma.
Treatment: Nivolumab Injectable Product · Nivolumab · Pembrolizumab — The purpose of this study is to see if people prefer immunotherapy treatment for kidney cancer delivered intravenously or subcutaneously and if it is practical for participants to receive labs at home and have a video (telehealth) visit with their doctor prior to their day of treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Renal Cell Carcinoma
Prior therapy
Must have received: immune checkpoint inhibitor (nivolumab, pembrolizumab) — renal cell carcinoma, any indication
Patient is receiving standard of care treatment for renal cell carcinoma for one of the following indications: 1) NIVO monotherapy as maintenance, after ipilimumab and NIVO induction (up to 4 doses), 2) NIVO monotherapy as single-agent treatment, OR 3) adjuvant PEMBRO monotherapy or combination therapy with belzutifan.
Cannot have received: investigational agent
Patients are unable to receive investigational agents on other clinical trial protocols
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester (All Protocol Activities) · Harrison, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07872553 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational agent disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages